

HLS Therapeutics Inc.

HLS Therapeutics to Host Q1 Fiscal 2022 Financial Results Conference Call

TORONTO, April 28, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 Fiscal 2022 financial results on Thursday, May 5, 2022. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Gilbert Godin, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. **Slides to accompany management's prepared remarks will be available to view via the webcast.**

CONFERENCE ID:	40019581
DATE:	Thursday, May 5, 2022
TIME:	8:30 a.m. ET
DIAL-IN NUMBER:	1-888-664-6392 or 416-764-8659
WEBCAST LINK:	https://produceredition.webcasts.com/starthere.jsp?ei=1544747&tp_key=e96e137a22
TAPED REPLAY:	1-888-390-0541 or 416-764-8677
REPLAY CODE:	019581

The taped replay will be available for 14 days and the archived webcast will be available for 365 days.

A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.

ABOUT HLS THERAPEUTICS INC.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

For further information: Dave Mason, Investor Relations, HLS Therapeutics Inc. (416) 247-9652, d.mason@hlstherapeutics.com

<https://hlstherapeutics.investorroom.com/2022-04-28-HLS-Therapeutics-to-Host-Q1-Fiscal-2022-Financial-Results-Conference-Call>